CHOSA to Unveil Predictive Data for Cisplatin Response in Lung Cancer at end Q2 2025 – Advancing Precision Medicine for the World’s Most Widely Used Cancer Drug
The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail.
26, March 2025 – CHOSA today announced the expected release timeline for results from a blinded, retrospective study using its Drug Response Predictor to assess cisplatin efficacy in lung cancer. The study, based on patients from the SPLENDOUR trial treated with platinum-based chemotherapy, aims to distinguish responders from non-responders. Results are anticipated by the end of Q2 2025.
Cisplatin is widely used in lung cancer treatment, benefiting a significant portion of patients. As one of the most effective and commonly used chemotherapy agents, understanding which patients will respond to cisplatin is crucial for optimizing treatment strategies and improving patient outcomes. Conducted in collaboration with leading international lung cancer experts, this study leverages clinical data already gathered from a large-scale trial to predict which patients benefit from cisplatin treatment and which do not and is consequently a very cost-effective way to run clinical trials.
CHOSA will apply its proprietary algorithm, based on a 205-gene test, to predict cisplatin treatment outcomes for patients from the SPLENDOUR trial. The trial included more than 500 patients and tissue is available from approximately 240 patients. CHOSA's study will provide the following key insights:
- Cisplatin Prediction Data: This will contribute to the validation of CHOSA’s algorithm based on c. 80 patients, following its validation in a late-stage, prospective breast cancer trial and two previous lung cancer studies using cisplatin as adjuvant therapy.
- Carboplatin Prediction Data: This will represent the first prediction data on carboplatin in lung cancer using the Platin-DRP, based on approximately 80 patients. As the study progresses and more patients treated with carboplatin are included, further analysis will allow for validation in an additional c. 80 patients.
- Testing NanoString Technology: CHOSA will also evaluate a novel technical prediction method, NanoString, expanding its capabilities and providing an additional platform for future commercialization.
Cisplatin and its sister molecule carboplatin are used in 16 different cancer indications and have been cornerstones in lung cancer chemotherapy for decades. Complementing the progress seen in immunotherapy platinum drugs continue to play a vital role in treatment regimens, including combinations with PD-1/PD-L1 inhibitors such as Keytruda and Opdivo.
The DRP tool is expected to play a critical role in the continued success of PD-1 and PD-L1 therapies. With the PD-1/PD-L1 market currently valued at $60 billion per year, CHOSA’s innovation could be pivotal in advancing the personalization of next-generation immuno-oncology.
For additional information, contact:
Peter Buhl Jensen, CEO
Peter@chosa.bio
+ 45 21 60 89 22
About the SPLENDOUR trial
more than 500 patients with advanced lung cancer received platinum-based therapy.
Tumor samples from the study are available for platinum sensitivity analysis. These will allow CHOSA to utilize biopsies from an already performed high-quality study, and in a very cost-effective way obtain useful clinical data aimed to pave the way to commercialization. Platinum drugs are used in almost all medical treatments of lung cancer and CHOSA will determine the Cisplatin-DRP accuracy in the prediction of tumor response to cisplatin or carboplatin chemotherapy. The study is expected to give pivotal data on the way for CHOSA’s test in clinical guidelines and regulatory approval.
The study will be done in collaboration with the ETOP IBCSG Partners Foundation and the European Organisation for Research and Treatment of Cancer (EORTC) SPLENDOUR Trial lung cancer experts, Professor Solange Peters and Professor Rolf Stahel. CHOSA will perform the analyses at Allarity’s laboratories.
The SPLENDOUR trial is described at https://pubmed.ncbi.nlm.nih.gov/32565388/
Background
Cisplatin and its sister molecule carboplatin have been cornerstones in lung cancer chemotherapy for decades. Despite advances in immunotherapy, platinum drugs remain critical in treatment regimens, including combinations with PD-1/L1 inhibitors. While numerous efforts to predict cisplatin efficacy have failed, the Cisplatin-DRP, based on a 205-gene biomarker signature, has shown promising results in other settings, including adjuvant therapy in NSCLC and progression-free survival in breast cancer.
This study will explore the predictive potential of the Cisplatin-DRP not only in cisplatin-treated patients but also in those treated with carboplatin. Data from the SPLENDOUR trial provides a unique opportunity to validate this tool in a large cohort, potentially confirming its utility across both drugs. Future research will aim to determine whether the Cisplatin-DRP can predict the effectiveness of combinations of platinum drugs with PD-1/L1 inhibitors.
CHOSA in short
CHOSA Oncology AB is an oncology biotechnology company led by a proven international team with veteran specialists in oncology; drug development; running clinical trials; regulatory expertise; and business development. CHOSA intends to enter into agreements for partnership or sublicensing of LiPlaCis® and the DRP®.
About Cisplatin-DRP, a test to predict if cisplatin treatment is likely to be successful
CHOSA is focused on late-stage clinical development of LiPlaCis® and its DRP® drug response predictor to which it has worldwide rights. The cisplatin DRP is the only proven test to foresee and thereby select who to treat and who will benefit from cisplatin. Breast: We have strong phase 2b data in metastatic breast cancer, demonstrating that patients selected by DRP® responded better to treatment; have longer progression-free survival; and maybe even an overall longer total survival than those patients who were identified as unlikely to respond well to the treatment.
Lung: The cisplatin DRP has previously shown its ability to foresee the value of cisplatin therapy in lung cancer. Cisplatin therapy after surgery is a gold standard that increases lung cancer cure, but not always, and until now the doctors do not know who will benefit from cisplatin and who should have something else. This is where the cisplatin DRP is a potential game changer, especially in new neoadjuvant treatment where immunotherapy obtains high efficacy rates when combined with cisplatin doubles. Cisplatin DRP was validated in a blinded retrospective study in two lung cancer patient cohorts receiving cisplatin after surgery to kill remaining tumor cells. Thus, patients with the 10% highest scores had a 3-year survival of 90% whereas the patients with the lowest 10% score had much lower survival with only 40% surviving 3 years1.
Immunotherapy There is a new development that adds further value to our DRP. Cisplatin has often been shown to activate the immune system (making cold tumors hot), which makes tumors susceptible to PD1 inhibitors. This synergy is particularly important but not limited to the treatment of lung cancer, bladder cancer, and head and neck cancer. In the ever-growing PD1 inhibitor market, where competition is fierce, our company stands out with the ability to predict if cisplatin will provide synergy with PD1. This can give the PD1 selling companies a significant competitive advantage.
1) Buhl et al PLOS One doi: 10.1371/journal.pone0194609
DRP® is a registered trademark of Allarity Therapeutics, Inc., and is used under license granted to CHOSA. LiPlaCis is in-licensed from Allarity Therapeutics Ltd (previous Oncology Venture ApS) and LiPlasome Pharma ApS.